吸入异丙托溴铵/沙丁胺醇联合肝素在老年慢性阻塞性肺病急性加重期的临床疗效

目的分析研究吸入异丙托溴铵/沙丁胺醇联合肝素在老年慢性阻塞性肺病急性加重期(AECOPD)的临床疗效及安全性。方法将68例AECOPD患者随机分为观察组38例和对照组30例,两组患者均采用吸氧、抗感染、止咳化痰及平喘等对症支持治疗。对照组在此基础上吸入异丙托溴铵/沙丁胺醇,观察组在对照组基础上加用肝素,观察记录治疗前后患者呼吸困难评分、肺功能等变化。结果两组患者治疗前呼吸困难评分比较差异无统计学意义(P﹥0.05),治疗2周后,两组患者呼吸困难评分均较治疗前有明显下降,且观察组下降较对照组更明显(P﹤0.05);治疗前后二组患者肺功能均有明显改善,观察组肺功能改善明显高于对照组,两组比较差异有统计学意义(P﹤0.05);观察组与对照组治疗前后对凝血功能的影响比较差异无统计学意义(P﹥0.05);两组均未出现明显不良反应。结论 AECOPD患者使用吸入异丙托溴铵/沙丁胺醇联合肝素治疗疗效显著,能明显改善患者的肺功能和临床症状,对凝血功能影响较小。

Clinical efficacy of inhaled ipratropium bromide/salbutamol combined with heparin on elderly patients with acute exacerbation of chronic obstructive pulmonary disease

OBJECTIVE To analyze the clinical efficacy and safety of inhaled ipratropium bromide/salbutamol combined with heparin in elderly patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).METHODS 68 patients with AECOPD were randomly divided into observation group of 38 patients and control group of 30 patients.Two groups were treated with symptomatic and supportive treatment.The control group inhaled ipratropium bromide/salbutamol,observation group were treat with ipratropium bromide/salbutamol combined with heparin.Dyspnea score and lung function changes were observed and recorded before and after the treatment.RESULTS Before treatment,dyspnea score between the 2 groups had no significant difference(P﹥0.05),But after 2 weeks of treatment,dyspnea score in both groups decreased significantly,and the observation group decreased more significantly than the control group(P﹤0.05);lung function was significantly improved in both groups after the treatment,but more significantly in the observation group(P﹤0.05);adverse reactions and coagulation function had no significant changes in both group(P﹥0.05).CONCLUSION Inhaled ipratropium bromide/albuterol combined with heparin can significantly improve the lung function and clinical symptom of AECOPD patients and have less impact on blood coagulation.